Nan Fung Trinity (Hk) LTD Biomarin Pharmaceutical Inc Transaction History

Nan Fung Trinity (Hk) LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$71.48 - $86.85 $4.53 Million - $5.51 Million	-63,400 Reduced 22.61%	217,014 $18 Million
Q1 2022 May 04, 2022	BUY	$74.28 - $92.69 $1.83 Million - $2.28 Million	24,600 Added 9.62%	280,414 $21.6 Million
Q2 2021 Aug 04, 2021	BUY	$75.51 - $84.79 $1.96 Million - $2.2 Million	25,900 Added 11.27%	255,814 $21.3 Million
Q1 2021 May 13, 2021	BUY	$74.73 - $90.69 $5.12 Million - $6.21 Million	68,500 Added 42.44%	229,914 $17.4 Million
Q4 2020 Feb 11, 2021	BUY	$72.61 - $90.2 $1.85 Million - $2.3 Million	25,500 Added 18.76%	161,414 $14.2 Million
Q3 2020 Nov 12, 2020	BUY	$71.87 - $131.03 $4.18 Million - $7.62 Million	58,150 Added 74.78%	135,914 $10.3 Million
Q4 2019 Feb 12, 2020	BUY	$64.27 - $86.37 $5 Million - $6.72 Million	77,764 New	77,764 $6.57 Million

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Nan Fung Trinity (Hk) LTD, based on Form 13F filings with the SEC.

Stay updated on Nan Fung Trinity (Hk) LTD with notifications on news.